{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:54:03Z","timestamp":1790614443880,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Baloxavir marboxil (formerly S-033188) is a prodrug of baloxavir acid (S-033447) and inhibits cap-dependent endonuclease, an essential protein involved in the initiation of viral transcription by cleaving capped mRNA bound to PB2. Its adverse event profile is comparable to oseltamivir but is still vulnerable to resistance. The single-dose baloxavir marboxil is an appealing antiviral regimen for the treatment of influenza among outpatients when compared with longer, twice-daily regimens of oral and inhaled neuraminidase inhibitors. This review focuses on the mode of action, antiviral activity, pharmacokinetics, clinical indications, and safety profiles of this drug. Considerations for formulary addition and its place in therapy are also discussed.<\/jats:p>","DOI":"10.1093\/cid\/ciaa107","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T12:17:41Z","timestamp":1580818661000},"page":"1790-1794","source":"Crossref","is-referenced-by-count":58,"title":["Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza"],"prefix":"10.1093","volume":"71","author":[{"given":"George M","family":"Abraham","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA"},{"name":"University of Massachusetts Medical School, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob B","family":"Morton","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Saint Vincent Hospital, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis D","family":"Saravolatz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ascension St John Hospital, Grosse Pointe Woods, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"2020102308132518800_CIT0001","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy866","article-title":"Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020102308132518800_CIT0002"},{"key":"2020102308132518800_CIT0003","doi-asserted-by":"crossref","first-page":"e02460","DOI":"10.1128\/AAC.02460-16","article-title":"The PA endonuclease inhibitor RO-7 protects mice from lethal challenge with influenza A or B viruses","volume":"61","author":"Jones","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020102308132518800_CIT0004","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature07745","article-title":"The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit","volume":"458","author":"Dias","year":"2009","journal-title":"Nature"},{"key":"2020102308132518800_CIT0005"},{"key":"2020102308132518800_CIT0006","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s40261-018-0710-9","article-title":"Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings","volume":"38","author":"Koshimichi","year":"2018","journal-title":"Clin Drug Investig"},{"key":"2020102308132518800_CIT0007","first-page":"302","article-title":"Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil","volume":"9","author":"Takashita","journal-title":"Front Microbiol"},{"key":"2020102308132518800_CIT0008","first-page":"153","article-title":"Influenza A: understanding the viral life cycle","volume":"82","author":"Samji","year":"2009","journal-title":"Yale J Biol Med"},{"key":"2020102308132518800_CIT0009","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci Rep"},{"key":"2020102308132518800_CIT0010","first-page":"1","article-title":"Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza","author":"Uehara","year":"2019","journal-title":"J Infect Dis"},{"key":"2020102308132518800_CIT0011","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/jac\/dky462","article-title":"Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection","volume":"74","author":"Fukao","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020102308132518800_CIT0012","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.antiviral.2016.06.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014\u20132015","volume":"132","author":"Hurt","year":"2016","journal-title":"Antiviral Res"},{"key":"2020102308132518800_CIT0013","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"2020102308132518800_CIT0014","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.xphs.2018.12.005","article-title":"Population pharmacokinetic and exposure-response analyses of baloxavir marboxil in adults and adolescents including patients with influenza","volume":"108","author":"Koshimichi","year":"2019","journal-title":"J Pharm Sci"},{"key":"2020102308132518800_CIT0015","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3851\/IMP2957","article-title":"Viral shedding and susceptibility to oseltamivir in hospitalized immunocompromised patients with influenza in the Influenza Resistance Information Study (IRIS)","volume":"20","author":"Fraaij","year":"2015","journal-title":"Antivir Ther"},{"key":"2020102308132518800_CIT0016","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/j.1469-0691.2010.03399.x","article-title":"Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients","volume":"17","author":"Giannella","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2020102308132518800_CIT0017","author":"Hoffmann-La"},{"key":"2020102308132518800_CIT0018","volume-title":"Lexi-Drugs","author":"Oseltamivir","year":"2019"},{"key":"2020102308132518800_CIT0019","volume-title":"Lexi-Drugs","author":"Baloxavir marboxil","year":"2019"},{"key":"2020102308132518800_CIT0020","author":"Hoffmann-La"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa107\/33462928\/ciaa107.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/7\/1790\/33994656\/ciaa107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/7\/1790\/33994656\/ciaa107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T12:27:34Z","timestamp":1603456054000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/7\/1790\/5722404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,2,5]]},"published-print":{"date-parts":[[2020,10,23]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa107","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10,1]]},"published":{"date-parts":[[2020,2,5]]}}}